DNLI: Denali Corp Forward P/S Multiple
Geopolitical tensions and the decoupling of ties are hindering global medical research, as reflected in the forward P/S dynamics of Denali Therapeutics (DNLI), where the parameter value equals 140.10. Breakthrough developments in crossing the blood-brain barrier via the TV platform are accelerating the creation of Alzheimer's and Parkinson's therapies. Meanwhile, strategic alliances with pharma behemoths and a diversified pipeline significantly mitigate the financial risks for this young biotech.
Metric breakdowns and analytics for denalitherapeutics.com (DNLI)
- stock price and consensus target price:
- market capitalization information:
- issuer book value statistics:
- debt and solvency information:
Total Debt to Capital Denali Therapeutics|DNLI - Long-Term Debt to Capital|Short-Term Debt to Equity Denali Therapeutics|DNLI - Company Aggregate Indebtedness|Debts to Book Capitalization Denali Corp|DNLI - Long-Term Debt|Company Current Liabilities Denali Therapeutics|Quick Liquidity Indicator denalitherapeutics.com
- financial results and valuation multiples details:
DNLI - Profit After Payment of Taxes|Projected Future Earnings Denali Therapeutics|DNLI - Business Payback Period|Forward P/E Multiple denalitherapeutics.com|DNLI - Price/Earnings to Growth Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Denali Therapeutics Inc|DNLI - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Denali Therapeutics|DNLI - Earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months denalitherapeutics.com|DNLI - Earnings per share growth this year|Net earnings per share growth forecast for next year Denali Therapeutics
- revenue and sales details:
Fundamental valuation:denalitherapeutics.com DNLI
To protect capital from volatility, it is essential for an investor to determine the equilibrium point between the market price and future cash flows. The unique blood-brain barrier crossing platform of Denali Therapeutics (DNLI) creates high added value, which the forward P/S ratio translates into a market capitalization valuation relative to expected revenue, allowing for a precise calibration of the asset's fundamental overheating within a portfolio.
Competitor analysis
Forward P/S Multiple BIIB (Biogen Idec)|Market Cap to Expected Sales Ratio Neurocrine Corp (NBIX)|RGC: Forward Price-to-Revenue Multiple|Forward Price to Sales AXSM (Axsome Therapeutics)|ACAD: Forward P/S Multiple|Xenon Pharmaceuticals Inc. - Forward Price to Sales|Price-to-Projected Revenue Ratio Viking Pharma|SUPN: Forward Price to Sales|Forward P/S Multiple CPRX|Market Cap to Expected Sales Ratio Harmony Biosciences|Biohaven Ltd - Forward Price-to-Revenue Multiple|Forward P/S Multiple Amylyx Pharmaceuticals, Inc. AMLX|TRVI: Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Praxis Corp PRAX|AVXL: Forward P/S Multiple|CBLL (ceribell.com) - Price-to-Projected Revenue Ratio|PRTA (Prothena Corporation) - Forward P/S Multiple|Forward Price-to-Revenue Multiple alector.com (ALEC)|Price-to-Projected Revenue Ratio Annexon, Inc. (ANNX)|OMER - Market Cap to Future Revenue Ratio|Forward P/S Multiple NGNE (Neurogene Inc)|AC Immune (ACIU) - Market Cap to Future Revenue Ratio|Voyager Therapeutics Inc - Forward P/S Multiple|Neumora (NMRA) - Forward Price-to-Revenue Multiple|SCLX: Forward P/S Multiple|TVGN - Market Cap to Expected Sales Ratio|ACOG (Alpha Cognition Inc) - Forward P/S Multiple|Forward Price-to-Revenue Multiple cogrx.com (CGTX)|Price-to-Projected Revenue Ratio Inhibikase Therapeutics Inc (IKT)|Market Cap to Expected Sales Ratio Cassava Sciences|Forward P/S Multiple ASRT (Assertio Holdings)|COYA - Forward Price-to-Revenue Multiple|vistagen.com - Forward P/S Multiple|OVID: Price-to-Projected Revenue Ratio|Acumen Pharmaceuticals, Inc (ABOS) - Price-to-Projected Revenue Ratio|CervoMed Inc - Forward Price to Sales|Price-to-Projected Revenue Ratio Alterity Therapeutics Limited|clene.com (CLNN) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple PEPG (PepGen Inc)|Forward P/S Multiple jupiterneurosciences.com (JUNS)|Price-to-Projected Revenue Ratio Relmada Therapeutics, Inc. RLMD|ANVS: Market Cap to Projected Revenue|Grace Tx - Forward P/S Multiple|AIFF (Firefly Neuroscience Inc) - Market Cap to Projected Revenue|KLTO: Forward P/S Multiple|NeuroSense Therapeutics, Ltd. (NRSN) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Reviva Pharmaceuticals, Inc.|Forward Price-to-Revenue Multiple metaviatx.com (MTVA)|Forward P/S Multiple NRXS|HSDT - Market Cap to Future Revenue Ratio|Passage Bio, Inc. - Forward Price-to-Revenue Multiple|bionomics.com.au (NEUP) - Market Cap to Future Revenue Ratio|Minerva - Forward P/S Multiple|Forward Price to Sales ATHA (Athira Pharma Inc)|ADXN: Forward P/S Multiple|Market Cap to Projected Revenue ALZN|CYCN (Cyclerion Therapeutics Inc.) - Forward P/S Multiple|PTIX (Protagenic Therapeutics) - Price to Expected Revenue Ratio|Forward P/S Multiple KTTA|Market Cap to Expected Sales Ratio Cortigent|Forward P/S Multiple ATXI (avenuetx.com)|BrainStorm Cell Therapeutics Inc. - Price-to-Projected Revenue Ratio|Cara Therapeutics Inc. - Forward P/S Multiple|Chromocell Therapeutics (CHRO) - Forward Price-to-Revenue Multiple|ELYM: Forward P/S Multiple|Forward Price-to-Revenue Multiple Intra-Cellular Therapies Inc.|LBPH (Longboard Pharmaceuticals Inc) - Forward P/S Multiple|Marinus - Future Price to Revenue|Forward P/S Multiple NKGN|NRBO (NeuroBo Pharmaceuticals) - Forward Price to Sales|Forward P/S Multiple SAGE (Sage Therapeutics Inc)|Market Cap to Expected Sales Ratio Synaptogenix Inc. (SNPX)|TRVN - Price-to-Projected Revenue Ratio|vigilneuro.com (VIGL) - Forward Price-to-Revenue Multiple|WENA: Forward P/S Multiple|Cerevel Therapeutics, Inc. (CERE) - Forward P/S Multiple
